Daptomycin, recognized as the brand name antibiotic Cubicin, has a patent expiration of September 24, 2019. Cubist Pharmaceutical markets Cubicin and they recently released a report revealing surprisingly weak sales. Initially Cubist reported strong sales of Daptomycin for the first quarter of 2013, with an overall rise in their revenues due to this potent antibiotic.[…]
Weak Sales and a Recall of Daptomycin Reported
Antibacterial, Antibiotic, Drug Research & Development API, Patent Expiration 2019 Tags: antibiotic May 08, 2014
Transfer of Rights for Cetrorelix a Boon for Merck Serono
Drug Research & Development API, Patent Expiration 2019, Synthetic Peptide Apr 25, 2014
Used to regulate hormone responses in female patients undergoing infertility treatment, Cetrorelix, is also known as the brand name Cetrotide. On April 17, 2013 Aeterna Zentaris announced the transfer of the manufacturing rights of this powerhouse product to Merck Serono. With the patent for Cetrotide set to expire on April 23, 2019, this transfer of[…]
Conivaptan Can Combat Hyponatremia
Patent Expiration 2019 Tags: congestive heart failure Mar 17, 2014
A recently published study in the American Journal of Kidney Diseases offered a sobering look at the incidence and seriousness of Hyponatremia among hemodialysis patients. Published on April 13, 2013 the aforementioned study focused on patients on hemodialysis and how the condition of Hyponatremia significantly affected their health and mortality risk. Patients who were diagnosed[…]
Calcitriol Poised for FDA Approval as Vitamin D to Treat Hypocalcemia
Hormonal Agent, Hypocalcemia, Patent Expiration 2019 Tags: hypocalcemia Feb 10, 2014
The biopharmaceutical company Rockwell Medical is anxiously awaiting approval from the FDA for its injectable Vitamin D drug, Calcitriol CAS# 32222-06-3. This promising new indication approval was submitted in April of 2013, with the goal of better managing hypocalcemia in patients who experience chronic renal dialysis. As an active injectable treatment known as the brand[…]
Desonide Continues to Thrive as a Treatment for Atopic Dermatitis
OTC and Compounding Product, Patent Expiration 2019 Feb 03, 2014
On June 4, 2013 Aqua Pharmaceuticals announced its acquisition of the brand name foam of Desonide, coined Verdeso, from Stiefel Pharmaceuticals. This announcement was extremely positive for Aqua Pharmaceuticals, as they already hold a thriving lineup of dermatologic products, such as Fluoroplex and Cordran. The addition of Verdeso, a foam formulation of Desonide, has filled[…]
Diclofenac Potassium Nets $3 Million in First Quarter of 2013
Anti-Inflammatory, Drug Research & Development API, Patent Expiration 2019 Tags: NSAIDRheumatoid ArthritisWarfarin Jan 02, 2014
Diclofenac Potassium CAS# 15307-81-0, also known as the brand name Zipsor, netted an astounding three million dollars in sales for the first quarter of 2013. Depomed Incorporated, who markets the NSAID, recently reported their better than expected financials regarding this efficacious treatment for arthritis and pain. The patent for Zipsor expires on July 15, 2019,[…]
Difluprednate Stands the Test of Time
Drug Research & Development API, OTC and Compounding Product, Patent Expiration 2019 Dec 23, 2013
The first topical steroid, Difluprednate, known as the brand name Durezol, continues to prove itself year after year. As a difluorinated derivative of prednisolone, Difluprednate has been indicated to treat both eye pain and inflammation after surgery, as well as anterior uveitis. A recent clinical trial published on June 18, 2013 indicated success for participants[…]
Eplerenone for Acute ST-Segment Elevation Myocardial Infarction
Drug Research & Development API, Hormonal Agent, Patent Expiration 2019 Tags: congestive heart failurehypertensionPfizer Nov 13, 2013
Exciting results were revealed in Mid-March of 2013 when the REMINDER trial touted the success of Eplerenone for treating acute ST-Segment Elevation Myocardial Infarction, also known as STEMI. The results from this study were presented at the 62nd Annual Scientific Session of the American College of Cardiology, by Pfizer, who markets Inspra which is the[…]
Ethinyl Estradiol and Norgestimate 2012 U.S. Sales Exceed $425 Million
Hormonal Agent, OTC and Compounding Product, Patent Expiration 2019 Nov 12, 2013
Ethinyl Estradiol CAS# 57-63-6 Ethinyl Estradiol, CAS number 57-63-6 and Norgestimate, CAS number 35189-28-7, are both integral components in the blockbuster birth control pill Ortho Tri-Cyclen Lo. Mylan and Janssen, who market Ortho Tri-Cyclen Lo, reported an astounding 425.5 million dollars in sales for the United States for the 2012 year. With the patent for[…]
Ranolazine Brings Relief for Patients with Chronic Angina and Type 2 Diabetes
Anti-Diabetic, Drug Research & Development API, Patent Expiration 2019 Tags: type 2 Diabetes Nov 11, 2013
Ranolazine shined at the American College of Cardiology’s 62nd Annual Scientific Session in Mid-March 2013 when data from a phase 4 study, coined TERISA revealed positive findings. Known as the brand name Ranexa, Ranolazine is an efficacious treatment for chronic angina. The TERISA study, standing for Type 2 Diabetes Evaluation of Ranolazine In Subjects With[…]
- 1
- 2
